Page 154 - Read Online

McKenna et al Hypoxia in prostate cancer

CD, Jones SJM, Juhl H, Kahles A, Kane CJ, Kasaian K, Kerger M, Boutros PC, Bristow RG. Tumour genomic and microenvironmental
Khurana E, Kim J, Klein RJ, Kucherlapati R, Lacombe L, Ladanyi heterogeneity for integrated prediction of 5-year biochemical
M, Lai PH, Laird PW, Lander ES, Latour M, Lawrence MS, Lau K, recurrence of prostate cancer: a retrospective cohort study. Lancet
LeBien T, Lee D, Lee S, Lehmann KV, Leraas KM, Leshchiner I, Oncol 2014;15:1521-32.
Leung R, Libertino JA, Lichtenberg TM, Lin P, Linehan WM, Ling 79. Ragnum HB, Vlatkovic L, Lie AK, Axcrona K, Julin CH, Frikstad
S, Lippman SM, Liu J, Liu W, Lochovsky L, Loda M, Logothetis KM, Hole KH, Seierstad T, Lyng H. The tumour hypoxia marker
C, Lolla L, Longacre T, Lu YL, Luo JH, Ma Y, Mahadeshwar pimonidazole reflects a transcriptional programme associated with
HS, Mallery D, Mariamidze A, Marra MA, Mayo M, McCall S, aggressive prostate cancer. Br J Cancer 2015;112:382-90.
McKercher G, Meng S, Mes-Masson AM, Merino MJ, Meyersson 80. Luu HN, Lin HY, Sorensen KD, Ogunwobi OO, Kumar N,
M, Mieczkowski PA, Mills GB, Shaw KRM, Minner S, Moinzadeh Chornokur G, Phelan C, Jones D, Kidd L, Batra J, Yamoah K,
A, Moore RA, Morris S, Morrison C, Mose LE, Mungall AJ, Murray Berglund A, Rounbehler RJ, Yang M, Lee SH, Kang N, Kim SJ, Park
BA, Myers JB, Naresh R, Nelson J, Nelson MA, Nelson PS, Newton JY, Di Pietro G. miRNAs associated with prostate cancer risk and
Y, Noble MS, Noushmehr H, Nykter M, Pantazi A, Parfenov M, Park progression. BMC Urol 2017;17.
PJ, Parker JS, Paulauskis J, Penny R, Perou CM, Piche A, Pihl T, 81. Lynch SM, O’Neill KM, McKenna MM, Walsh CP, McKenna DJ.
Pinto PA, Prandi D, Protopopov A, Ramirez NC, Rao A, Rathmell Regulation of miR-200c and miR-141 by methylation in prostate
WK, Ratsch G, Ren XJ, Reuter VE, Reynolds SM, Rhie SK, Rieger- cancer. Prostate 2016;76:1146-59.
Christ K, Roach J, Robertson AG, Robinson B, Rubin MA, Saad F, 82. Dang K, Myers KA. The role of hypoxia-induced miR-210 in cancer
Sadeghi S, Saksena G, Saller C, Salner A, Sanchez-Vega F, Sander progression. Int J Mol Sci 2015;16:6353-72.
C, Sandusky G, Sauter G, Sboner A, Scardino PT, Scarlata E, Schein 83. Huang X, Le QT, Giaccia AJ. MiR-210-micromanager of the hypoxia
JE, Schlomm T, Schmidt LS, Schultz N, Schumacher SE, Seidman J, pathway. Trends Mol Med 2010;16:230-7.
Neder L, Seth S, Sharp A, Shelton C, Shelton T, Shen H, Shen RL, 84. Taddei ML, Cavallini L, Comito G, Giannoni E, Folini M, Marini
Sherman M, Sheth M, Shi Y, Shih J, Shmulevich I, Simko J, Simon R, A, Gandellini P, Morandi A, Pintus G, Raspollini MR, Zaffaroni N,
Simons JV, Sipahimalani P, Skelly T, Sofia HJ, Soloway MG, Song Chiarugi P. Senescent stroma promotes prostate cancer progression:
XZ, Sorcini A, Sougnez C, Stepa S, Stewart C, Stewart J, Stuart JM, the role of miR-210. Mol Oncol 2014;8:1729-46.
Sullivan TB, Sun C, Sun HD, Tam A, Tan DH, Tang JB, Tarnuzzer 85. Haldrup C, Kosaka N, Ochiya T, Borre M, Hoyer S, Orntoft TF,
R, Tarvin K, Taylor BS, Teebagy P, Tenggara I, Tetu B, Tewari A, Sorensen KD. Profiling of circulating microRNAs for prostate cancer
Thiessen N, Thompson T, Thorne LB, Tirapelli DP, Tomlins SA, biomarker discovery. Drug Deliv Transl Res 2014;4:19-30.
Trevisan FA, Troncoso P, True LD, Tsourlakis MC, Tyekucheva S, 86. Cheng HH, Mitchell PS, Kroh EM, Dowell AE, Chery L, Siddiqui J,
Van Allen E, Van den Berg DJ, Veluvolu U, Verhaak R, Vocke CD, Nelson PS, Vessella RL, Knudsen BS, Chinnaiyan AM, Pienta KJ,
Voet D, Wan YH, Wang QG, Wang WY, Wang ZN, Weinhold N, Morrissey C, Tewari M. Circulating microRNA profiling identifies a
Weinstein JN, Weisenberger DJ, Wilkerson MD, Wise L, Witte J, Wu subset of metastatic prostate cancer patients with evidence of cancer-
CC, Wu JY, Wu Y, Xu AW, Yadav SS, Yang LM, Yang LX, Yau C, associated hypoxia. PLoS One 2013;8:e69239.
Ye HH, Yena P, Zeng T, Zenklusen JC, Zhang HL, Zhang JH, Zhang 87. Mateo J, Carreira S, Sandhu S, Miranda S, Mossop H, Perez-Lopez R,
JS, Zhang W, Zhong Y, Zhu K, Zmuda E; Cancer Genome Atlas Rodrigues DN, Robinson D, Omlin A, Tunariu N, Boysen G, Porta N,
Research Network. The molecular taxonomy of primary prostate Flohr P, Gillman A, Figueiredo I, Paulding C, Seed G, Jain S, Ralph C,
cancer. Cell 2015;163:1011-25. Protheroe A, Hussain S, Jones R, Elliott T, McGovern U, Bianchini
74. Ciccarese C, Santoni M, Brunelli M, Buti S, Modena A, Nabissi D, Goodall J, Zafeiriou Z, Williamson CT, Ferraldeschi R, Riisnaes
M, Artibani W, Martignoni G, Montironi R, Tortora G, Massari F. R, Ebbs B, Fowler G, Roda D, Yuan W, Wu YM, Cao X, Brough R,
AR-V7 and prostate cancer: the watershed for treatment selection? Pemberton H, A’Hern R, Swain A, Kunju LP, Eeles R, Attard G, Lord
Cancer Treat Rev 2016;43:27-35. CJ, Ashworth A, Rubin MA, Knudsen KE, Feng FY, Chinnaiyan AM,
75. Buffa FM, Harris AL, West CM, Miller CJ. Large meta-analysis of Hall E, de Bono JS. DNA-repair defects and olaparib in metastatic
multiple cancers reveals a common, compact and highly prognostic prostate cancer. N Engl J Med 2015;373:1697-708.
hypoxia metagene. Br J Cancer 2010;102:428-35. 88. Nordsmark M, Bentzen SM, Overgaard J. Measurement of human
76. Winter SC, Buffa FM, Silva P, Miller C, Valentine HR, Turley H, tumour oxygenation status by a polarographic needle electrode.
Shah KA, Cox GJ, Corbridge RJ, Homer JJ, Musgrove B, Slevin An analysis of inter- and intratumour heterogeneity. Acta Oncol
N, Sloan P, Price P, West CML, Harris AL. Relation of a hypoxia 1994;33:383-9.
metagene derived from head and neck cancer to prognosis of multiple 89. Becker A, Hansgen G, Bloching M, Weigel C, Lautenschlager C,
cancers. Cancer Res 2007;67:3441-9. Dunst J. Oxygenation of squamous cell carcinoma of the head and
77. Eustace A, Mani N, Span PN, Irlam JJ, Taylor J, Betts GN, Denley neck: comparison of primary tumors, neck node metastases, and
H, Miller CJ, Homer JJ, Rojas AM, Hoskin PJ, Buffa FM, Harris AL, normal tissue. Int J Radiat Oncol Biol Phys 1998;42:35-41.
Kaanders JH, West CM. A 26-gene hypoxia signature predicts benefit 90. Le QT, Kovacs MS, Dorie MJ, Koong A, Terris DJ, Pinto HA,
from hypoxia-modifying therapy in laryngeal cancer but not bladder Goffinet DR, Nowels K, Bloch D, Brown JM. Comparison of the
cancer. Clin Cancer Res 2013;19:4879-88. comet assay and the oxygen microelectrode for measuring tumor
78. Lalonde E, Ishkanian AS, Sykes J, Fraser M, Ross-Adams H, Erho oxygenation in head-and-neck cancer patients. Int J Radiat Oncol
N, Dunning MJ, Halim S, Lamb AD, Moon NC, Zafarana G, Warren Biol Phys 2003;56:375-83.
AY, Meng XY, Thoms J, Grzadkowski MR, Berlin A, Have CL, 91. Falk SJ, Ward R, Bleehen NM. The influence of carbogen breathing
Ramnarine VR, Yao CQ, Malloff CA, Lam LL, Xie HL, Harding on tumour tissue oxygenation in man evaluated by computerised p02
NJ, Mak DYF, Chu KC, Chong LC, Sendorek DH, P’ng C, Collins histography. Br J Cancer 1992;66:919-24.
CC, Squire JA, Jurisica I, Cooper C, Eeles R, Pintilie M, Dal Pra 92. Le QT, Chen E, Salim A, Cao H, Kong CS, Whyte R, Donington
A, Davicioni E, Lam WL, Milosevic M, Neal DE, van der Kwast T, J, Cannon W, Wakelee H, Tibshirani R, Mitchell JD, Richardson

12 Journal of Cancer Metastasis and Treatment ¦ Volume 4 ¦ March 1, 2018